Develops experimental cancer therapies for people with blood cancers and solid tumors.
10-K for FY2025, filed Mar 19, 2026We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer…View ↗
Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that…View ↗
On March 31, 2022, we entered into an exclusive license agreement, or the GenFleet Agreement, with GenFleet Therapeutics (Shanghai), Inc.…View ↗
SELLAS licenses GPS and GPS Plus directly to 3D Medicines for development, manufacturing and commercialization in Greater China; it retained rights outside that territory.
10-K for FY2025, filed Mar 19, 2026
Competes with AbbVie, Genentech, Pfizer, Daiichi-Sankyo, Rigel Pharmaceuticals, Syndax Pharmaceuticals, Bristol Myers Squibb, Curis, Delta-Fly Pharma, AROG Pharmaceuticals, Sumitomo Dainippon Pharma, Cothera Bioscience, and Prelude Therapeutics
10-K for FY2025, filed Mar 19, 2026Companies developing novel products with similar indications to those we are pursuing and may pursue are expected to influence our ability…View ↗
Loading...